Liraglutide – Effects on Lean Body Mass, Muscle Mass and Prevention of Muscle Loss. A Comprehensive Literature Review
Authors:
- Michał OborskiMOMichał Oborski
- Krzysztof OborskiKOKrzysztof Oborski
- Szymon GórskiSGSzymon Górski
- Joanna OkupniarekJOJoanna Okupniarek
- Maria OchwatMOMaria Ochwat
- Michalina BartosikMBMichalina Bartosik
- Igor JętasiewiczIJIgor Jętasiewicz
- Jakub MiarczyńskiJMJakub Miarczyński
- Paweł PiechockiPPPaweł Piechocki
- Katarzyna BarczyńskaKBKatarzyna Barczyńska
Open Access
- 19 January 2026
- journal article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49, 67959
Abstract
Introduction and Purpose. Obesity is a major global health challenge, requiring effective long-term treatments. Liraglutide, a GLP-1 agonist, is effective for weight loss and reducing visceral fat. However, its impact on lean body mass (LBM) and muscle mass is crucial, as their loss can lead to sarcopenia, metabolic impairment, and weight regain. Therefore, this literature review systematically analyses liraglutide's effects on LBM and muscle mass in obesity and/or type 2 diabetes, and presents strategies to minimise potential muscle loss during therapy. Materials and methods. A systematic review of the scientific literature was conducted. Literature available in the PubMed and Google Scholar databases was searched using keywords. Results. The findings from clinical trials are not definitive. While several studies report a statistically significant loss of lean body mass (LBM), it remains proportionally smaller than fat loss and may constitute up to 40% of total weight reduction. Conversely, other studies—including the most recent ones—indicate that liraglutide primarily reduces adipose tissue. This effect preserves LBM and can enhance muscle quality by reducing intramuscular fat. The observed absolute decrease in LBM appears strongly correlated with total weight loss, implying it is a consequence of weight reduction itself rather than a specific drug-induced catabolic effect. Preliminary data also suggest liraglutide may have a direct anabolic and protective effect on skeletal muscle via modulation of signalling pathways. To mitigate muscle loss, pharmacotherapy should be combined with non-pharmacological interventions, such as a high-protein diet (1.2–1.6 g/kg bw/day) and regular resistance training. Combination therapies including anabolic agents also represent a promising approach.Keywords
This publication has 56 references indexed in Scilit:
- Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespanJournal of Endocrinological Investigation, 2025
- Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity?The Journal of nutrition, health and aging, 2025
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity SocietyThe American Journal of Clinical Nutrition, 2025
- Pharmacological Treatment of Obesity in Older AdultsDrugs & Aging, 2024
- Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trialJournal of Cachexia, Sarcopenia and Muscle, 2024
- Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesityObesity, 2022
- Liraglutide Does Not Adversely Impact Fat‐Free Mass LossObesity, 2021
- Intensive lifestyle modifications with or without liraglutide 3 mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot studyDiabetes & Metabolism, 2018
- Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series studyAging Clinical and Experimental Research, 2016
- Obesity and weight management in the elderly: A focus on menBest Practice & Research Clinical Endocrinology & Metabolism, 2013